Annexon
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1400 Sierra Point Pkwy Bldg C Ste 200, B...Phone Number
(650) 822-5500Website
www.annexonbio.comRevenue
$21.8 MillionStock Symbol
ANNXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
3
1
1
1
1
About Annexon
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company's first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company's second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Based on learnings from its initial trials, Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disRead more
Annexon Org Chart
Get the full picture
Sign in to uncover key details.
SB
Vice President Global Program Team Leader - O...
BS
Vice President, Medical Affairs
KR
Head Vice President, Medical Affairs Ophthalm...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Annexon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Annexon had a recent Job posting/layoffs
Product Launch: Get notified when Annexon launches new products
Check out if Annexon is spiking on competitors!
Check if Annexon has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Annexon, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Annexon has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Annexon
Earning: See what the market has to say on Annexon recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Annexon as Masked Content
Find 3 more new buyers
Compare Similar Companies to Annexon
Compare insights from companies similar to Annexon, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Annexon is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Annexon is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Annexon.
Annexon financials insights
Gather financial insights about Annexon, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$34M
2016
Series B
$44M
2018
Series C
$75M
2020
Unspecified
$100M
Stock Offering
$250.8M
2022
Share Placement
$130M
Annexon Tech Stack
A closer look at the technologies used by Annexon
Most Recent Scoops
Open Position
Person-Based
Events
Person-Based
Pharmaceuticals, Corporate Strategy
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Annexon News & Media
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
Annexon (NASDAQ:ANNX) executives outlined a series of expected clinical and regulatory updates across the company’s complement-focused pipeline during a session at the Jefferies Conference, highlighting programs in geographic atrophy, Guillain-Barré syndrome and cold agglutinin disease. Douglas LovAnnexon to Participate in Upcoming June Investor Conferences
BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following June investor conferences:Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2026, in accordance with Nasdaq Listing Rule 5635(cAnnexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Annexon, Inc. (ANNX) Bank of America Global Healthcare Conference 2026 May 13, 2026 2:20 PM EDTCompany ParticipantsDouglas Love - CEO, President &...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Annexon
Sign Up For FreeTo access detailed company insights
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, b... Read More
